研究单位:[1]Peking University First Hospital[2]Tongji Hospital of Huazhong University of Science and Technology[3]The Second People's Hospital of Fuyang[4]Ezhou Central Hospital[5]Huoshenshan Hospital of Wuhan
To evaluate the efficacy and safety of Anluohuaxian in blocking the progression of pulmonary fibrosis and improving lung function in patients with COVID-19.